ARTELO BIOSCIENCES, INC. Research and Development Expense
ARTELO BIOSCIENCES, INC. (ARTL) reported Research and Development Expense of $876.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- ARTELO BIOSCIENCES, INC. research and development expense for the quarter ending 2026-06-30 was $876.00K, a 53.18% decline year-over-year.
- ARTELO BIOSCIENCES, INC. research and development expense for the quarter ending 2026-03-31 was $773.00K, a 44.15% decline year-over-year.
- ARTELO BIOSCIENCES, INC. research and development expense for the quarter ending 2025-12-31 was $893.00K, a 63.93% decline year-over-year.
- ARTELO BIOSCIENCES, INC. research and development expense for the quarter ending 2025-09-30 was $1.27M, a 292.31% increase year-over-year.
- ARTELO BIOSCIENCES, INC. research and development expense for fiscal 2022 was $4.32M, a 14.27% increase from fiscal 2021.
- ARTELO BIOSCIENCES, INC. research and development expense for fiscal 2021 was $3.78M.
- ARTELO BIOSCIENCES, INC. research and development expense for fiscal 2021 was $2.84M, a 47.94% increase from fiscal 2020.
- ARTELO BIOSCIENCES, INC. research and development expense for fiscal 2020 was $1.92M, a 75.73% increase from fiscal 2019.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 4 month | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $876.00K 10-Q · filed 2026-08-12 | $1.65M 10-Q · filed 2026-08-12 | $2.54M derived: sum of 3 quarters · filed 2026-08-12 | $3.82M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $773.00K 10-Q · filed 2026-05-14 | $1.67M derived: sum of 2 quarters · filed 2026-05-14 | $2.94M derived: sum of 3 quarters · filed 2026-05-14 | $4.81M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $893.00K derived: 8-K 12 month − 10-Q 9 month · filed 2026-03-17 | $2.17M derived: sum of 2 quarters · filed 2026-03-17 | $4.04M derived: sum of 3 quarters · filed 2026-08-12 | $5.42M 8-K · filed 2026-03-17 | ||||
| 2025-09-30 | $1.27M 10-Q · filed 2025-11-12 | $3.15M derived: sum of 2 quarters · filed 2026-08-12 | $4.53M 10-Q · filed 2025-11-12 | $7.01M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $1.87M 10-Q · filed 2026-08-12 | $3.25M 10-Q · filed 2026-08-12 | $5.73M derived: sum of 3 quarters · filed 2026-08-12 | $6.06M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | $1.38M 10-Q · filed 2026-05-14 | $3.86M derived: sum of 2 quarters · filed 2026-05-14 | $4.18M derived: sum of 3 quarters · filed 2026-05-14 | $5.87M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $2.48M derived: 8-K 12 month − 10-Q 9 month · filed 2026-03-17 | $2.80M derived: sum of 2 quarters · filed 2026-03-17 | $4.49M derived: sum of 3 quarters · filed 2026-03-17 | $5.99M 8-K · filed 2026-03-17 | ||||
| 2024-09-30 | $325.00K 10-Q · filed 2025-11-12 | $2.01M derived: sum of 2 quarters · filed 2025-11-12 | $3.52M 10-Q · filed 2025-11-12 | $5.64M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | $1.69M 10-Q · filed 2025-08-13 | $3.19M 10-Q · filed 2025-08-13 | $5.32M derived: sum of 3 quarters · filed 2025-08-13 | $6.90M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $1.51M 8-K · filed 2025-07-11 | $3.63M derived: sum of 2 quarters · filed 2025-07-11 | $5.22M derived: sum of 3 quarters · filed 2025-07-11 | $5.97M derived: sum of 4 quarters · filed 2025-07-11 | ||||
| 2023-12-31 | $2.12M derived: 8-K 12 month − 10-Q 9 month · filed 2025-07-11 | $3.71M derived: sum of 2 quarters · filed 2025-07-11 | $4.46M derived: sum of 3 quarters · filed 2025-07-11 | $5.70M 8-K · filed 2025-07-11 | ||||
| 2023-09-30 | $1.58M 10-Q · filed 2024-11-12 | $2.34M derived: sum of 2 quarters · filed 2024-11-12 | $3.57M 10-Q · filed 2024-11-12 | $5.30M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $752.00K 10-Q · filed 2024-08-13 | $1.99M 10-Q · filed 2024-08-13 | $3.71M derived: sum of 3 quarters · filed 2024-08-13 | $4.79M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $1.24M 10-Q · filed 2024-05-13 | $2.96M derived: sum of 2 quarters · filed 2024-05-13 | $4.04M derived: sum of 3 quarters · filed 2024-05-13 | $5.09M derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $2.80M derived: sum of 2 quarters · filed 2024-03-25 | $3.86M derived: sum of 3 quarters · filed 2024-03-25 | $4.32M 10-K · filed 2024-03-25 | ||||
| 2022-09-30 | $1.08M 10-Q · filed 2023-11-13 | $2.13M derived: sum of 2 quarters · filed 2023-11-13 | $2.60M 10-Q · filed 2023-11-13 | $4.07M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $1.06M 10-Q · filed 2023-08-10 | $1.52M 10-Q · filed 2023-08-10 | $2.99M derived: sum of 3 quarters · filed 2023-08-10 | |||||
| 2022-03-31 | $464.00K 10-Q · filed 2023-05-11 | $1.94M derived: sum of 2 quarters · filed 2023-05-11 | ||||||
| 2021-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $1.94M 10-K · filed 2023-03-31 | $3.78M 10-K · filed 2023-03-31 | |||||
| 2021-11-30 | $1.27M 10-Q · filed 2022-01-12 | |||||||
| 2021-09-30 | $1.03M 10-Q · filed 2022-11-08 | $2.31M 10-Q · filed 2022-11-08 | ||||||
| 2021-08-31 | $615.46K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $2.84M 10-K · filed 2023-03-31 | ||||||
| 2021-06-30 | $970.00K 10-Q · filed 2022-08-09 | $1.28M 10-Q · filed 2022-08-09 | ||||||
| 2021-05-31 | $951.20K 10-Q · filed 2021-07-12 | $2.22M 10-Q · filed 2021-07-12 | ||||||
| 2021-03-31 | $307.00K 10-Q · filed 2022-05-12 | |||||||
| 2021-02-28 | $663.36K 10-Q · filed 2021-04-13 | $1.27M 10-Q · filed 2021-04-13 | $1.53M derived: sum of 3 quarters · filed 2022-03-21 | $1.79M derived: sum of 4 quarters · filed 2022-03-21 | ||||
| 2020-12-31 | $999.00K 10-KT · filed 2022-03-21 | |||||||
| 2020-11-30 | $595.00K 10-Q · filed 2022-01-12 | $594.63K 10-Q · filed 2021-01-14 | $867.08K derived: sum of 2 quarters · filed 2022-03-21 | $1.13M derived: sum of 3 quarters · filed 2022-03-21 | $1.85M derived: sum of 4 quarters · filed 2022-03-21 | |||
| 2020-08-31 | $272.08K derived: 10-KT 12 month − 10-Q 9 month · filed 2022-03-21 | $530.76K derived: sum of 2 quarters · filed 2022-03-21 | $1.25M derived: sum of 3 quarters · filed 2022-03-21 | $1.92M 10-KT · filed 2022-03-21 | $1.92M 10-K · filed 2020-11-04 | |||
| 2020-05-31 | $258.68K 10-Q · filed 2021-07-12 | $265.20K 10-Q · filed 2020-07-13 | $979.98K derived: sum of 2 quarters · filed 2021-07-12 | $1.65M 10-Q · filed 2021-07-12 | $1.88M derived: sum of 4 quarters · filed 2021-07-12 | |||
| 2020-02-29 | $721.31K 10-Q · filed 2021-04-13 | $714.78K 10-Q · filed 2020-04-13 | $1.39M 10-Q · filed 2021-04-13 | $1.38M 10-Q · filed 2020-04-13 | $1.62M derived: sum of 3 quarters · filed 2021-04-13 | $1.81M derived: sum of 4 quarters · filed 2021-04-13 | ||
| 2019-11-30 | $666.94K 10-Q · filed 2021-01-14 | $900.71K derived: sum of 2 quarters · filed 2021-01-14 | $1.08M derived: sum of 3 quarters · filed 2021-01-14 | $1.57M derived: sum of 4 quarters · filed 2021-01-14 | ||||
| 2019-08-31 | $233.77K derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-04 | $417.97K derived: sum of 2 quarters · filed 2020-11-04 | $907.95K derived: sum of 3 quarters · filed 2020-11-04 | $1.09M 10-K · filed 2020-11-04 | ||||
| 2019-05-31 | $184.20K 10-Q · filed 2020-07-13 | $674.18K derived: sum of 2 quarters · filed 2020-07-13 | $858.22K 10-Q · filed 2020-07-13 | $1.19M derived: sum of 4 quarters · filed 2020-07-13 | ||||
| 2019-02-28 | $489.98K 10-Q · filed 2020-04-13 | $674.02K 10-Q · filed 2020-04-13 | $1.01M derived: sum of 3 quarters · filed 2020-04-13 | $1.24M derived: sum of 4 quarters · filed 2020-04-13 | ||||
| 2018-11-30 | $184.04K 10-Q · filed 2020-01-14 | $516.50K derived: sum of 2 quarters · filed 2020-01-14 | $753.35K derived: sum of 3 quarters · filed 2020-01-14 | $1.40M derived: sum of 4 quarters · filed 2020-01-14 | ||||
| 2018-08-31 | $332.47K derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-12-18 | $569.31K derived: sum of 2 quarters · filed 2019-12-18 | $1.22M derived: sum of 3 quarters · filed 2019-12-18 | $1.25M 10-K/A · filed 2019-12-18 | ||||
| 2018-05-31 | $236.84K 10-Q · filed 2019-07-15 | $884.31K derived: sum of 2 quarters · filed 2019-07-15 | $917.39K 10-Q · filed 2019-07-15 | |||||
| 2018-02-28 | $647.47K 10-Q · filed 2019-04-15 | $477.36K 10-Q · filed 2018-04-16 | $680.54K 10-Q · filed 2019-04-15 | $510.43K 10-Q · filed 2018-04-16 | ||||
| 2017-11-30 | $33.08K 10-Q · filed 2019-01-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |